<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547037</url>
  </required_header>
  <id_info>
    <org_study_id>CR108471</org_study_id>
    <secondary_id>63723283LUC1002</secondary_id>
    <nct_id>NCT03547037</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers</brief_title>
  <official_title>A Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Subjects With Advanced Solid Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to identify the recommended Phase 2 dose (RP2D) of
      JNJ-63723283 as a monotherapy (Phase 1a part) and to identify the RP2D of JNJ-63723283 when
      administered in combination with Erdafitinib (Phase 1b part).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2018</start_date>
  <completion_date type="Anticipated">February 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1a and Phase 1b: Number of Participants with Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 6 weeks (maximum)</time_frame>
    <description>The DLTs are based on drug-related adverse events and defined as any of the following events: Infusion-related reactions, non-hematologic toxicity of Grade 3 or higher, or certain hematologic toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1a and Phase 1b: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)</measure>
    <time_frame>Up to 6 weeks (maximum)</time_frame>
    <description>Severity of DLT will be graded by using NCI-CTCAE, version 4.03. Severity scale ranges from Grade 1 to Grade 5 with Grades as follows: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-threatening), and Grade 5 (Death).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Number of Participants with Adverse Events and Immune-Related Adverse Event (irAE) by Severity</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Severity of Adverse Event will be graded by using NCI-CTCAE, version 4.03. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death) with Grades as follows: Grade 1 (Mild) Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life threatening) and Grade 5 (Death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a and Phase 1b: Number of Participants With Clinically Significant Changes in Vital Signs as a Measure of Safety and Tolerability</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Number of participants with clinically significant changes in the vital signs including blood pressure, pulse rate, and body temperature will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a and Phase 1b: Number of Participants With Clinical Laboratory Abnormalities as a Measure of Safety and Tolerability</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Number of participants with clinical laboratory abnormalities (clinical laboratory tests include the following: hematology panel, coagulation panel, serum chemistry panel, endocrine panel, serology and pregnancy test [women only]) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a and Phase 1b: Number of Participants With ECG Abnormalities as a Measure of Safety and Tolerability</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Number of participants with electrocardiogram (ECG) abnormalities will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a and Phase 1b: Maximum Serum Concentration (Cmax) of JNJ-63723283</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>The Cmax is the maximum observed serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a and Phase 1b: Serum Concentration Immediately Prior to the Next Drug Administration (Ctrough) of JNJ-63723283</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Ctrough is the serum concentration immediately prior to the next drug administration of any dose other than the first dose in a multiple dosing regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a and Phase 1b: Time to reach Maximum Observed serum Concentration (Tmax) of JNJ-63723283</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>The Tmax is defined as actual sampling time to reach maximum observed serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a and Phase 1b: Area Under the Serum Concentration-Time Curve Between 2 Defined Sampling Points, (t1 and t2) (AUC[t1-t2]) of JNJ-63723283</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>The AUC(t1-t2) is the area under the serum concentration-time curve between 2 defined sampling points, t1 and t2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a and Phase 1b: Elimination Half-Life (t1/2) of JNJ-63723283</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>T1/2 is the time measured for the serum concentration to decrease by 1 half to its original concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a and Phase 1b: Total Systemic Clearance (CL) of JNJ-63723283</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>CL is a quantitative measure of the rate at which JNJ-63723283 is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a and Phase 1b: Volume of Distribution at Steady-State (Vss) of JNJ-63723283</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution is the apparent volume of distribution at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Cmax of Erdafitinib</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Ctrough of Erdafitinib</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Ctrough is the plasma concentration immediately prior to the next drug administration of any dose other than the first dose in a multiple dosing regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a and Phase 1b: Number of Participants With Anti-JNJ 63723283 Antibodies</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Number of participants with anti-JNJ 63723283 antibodies will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Neoplasm</condition>
  <arm_group>
    <arm_group_label>Phase 1a: JNJ-63723283 (Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive monotherapy of JNJ-63723283 intravenously. The subsequent dose levels of JNJ-63723283 will be escalated using Bayesian logistic regression model (BLRM).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Erdafitinib Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive erdafitinib in combination with JNJ-63723283 which will be escalated using BLRM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-63723283</intervention_name>
    <description>JNJ-63723283 will be administered intravenously.</description>
    <arm_group_label>Phase 1a: JNJ-63723283 (Monotherapy)</arm_group_label>
    <arm_group_label>Phase 1b: Erdafitinib Combination</arm_group_label>
    <other_name>Cetrelimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erdafitinib</intervention_name>
    <description>Erdafitinib will be administered orally.</description>
    <arm_group_label>Phase 1b: Erdafitinib Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Radiographically, histologically, or cytologically confirmed advanced or refractory
             solid tumor(s) that is metastatic or unresectable, and previously received or was
             ineligible for standard treatment options. Participants with solid tumor(s) for which
             anti-PD-1 or anti-PD-L1 antibody as a monotherapy is approved in Japan are eligible.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Thyroid function laboratory values within normal range

          -  A woman must be: a) Not of childbearing potential; b) Of childbearing potential and
             practicing a highly effective, preferably user-independent method of contraception
             (failure rate of less than (&lt;) 1 percent (%) per year when used consistently and
             correctly) and agrees to remain on a highly effective method while receiving study
             intervention and continue for 5 months following discontinuation of JNJ-63723283 or 3
             months following discontinuation of erdafitinib, whichever is longer. Especially
             participants receiving erdafitinib must agree to use two contraceptive methods and one
             must be user-independent method; Examples of highly effective contraceptives include:
             user-independent methods: intrauterine device (IUD) or intrauterine contraceptive
             system (IUS) and user-dependent methods: combined (estrogen- and
             progestogen-containing) hormonal contraception or progesterone-containing hormonal
             contraception. c) Agree not to donate eggs (ova, oocytes), during the study and
             continue for 5 months following discontinuation of JNJ-63723283 or 3 months following
             discontinuation of erdafitinib, whichever is longer

          -  A male participant must wear a condom when engaging in any activity that allows for
             passage of ejaculate to another person and must agree not to donate sperm for 5 months
             following discontinuation of JNJ-63723283 or 5 months following discontinuation of
             erdafitinib, whichever is longer

        Exclusion Criteria:

          -  Had prior treatment with an anti-PD-1 antibody, anti-PD-L1 antibody or anti-PDL2
             antibody within 30 days of first study drug administration and/or has an ongoing Grade
             2 or higher immunotherapy-related toxicity. If the subject has an experience of
             treatment with these agents, the subject must not have had severe
             immunotherapy-related toxicity

          -  History of or concurrent interstitial lung disease

          -  Active autoimmune disease or a documented history of autoimmune disease that requires
             systemic steroids or immunosuppressive agents

          -  Grade 3 or higher toxicity effects from previous treatment with immunotherapy

          -  Has taken immunosuppressive doses of systemic medications, such as corticosteroids
             doses greater than (&gt;) 10 milligram per day (mg/day) prednisolone or equivalent),
             within 2 weeks before the planned first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K., Japan Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108471</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

